Literature DB >> 18667516

Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long-lived CD8+ memory T cells.

Gamal Badr1, Nathalie Bédard, Mohamed S Abdel-Hakeem, Lydie Trautmann, Bernard Willems, Jean-Pierre Villeneuve, Elias K Haddad, Rafick P Sékaly, Julie Bruneau, Naglaa H Shoukry.   

Abstract

The majority of acute hepatitis C virus (HCV) infections progress to chronicity and progressive liver damage. Alpha interferon (IFN-alpha) antiviral therapy achieves the highest rate of success when IFN-alpha is administered early during the acute phase, but the underlying mechanisms are unknown. We used a panel of major histocompatibility complex class I tetramers to monitor the phenotypic and functional signatures of HCV-specific T cells during acute HCV infection with different infection outcomes and during early IFN therapy. We demonstrate that spontaneous resolution correlates with the early development of polyfunctional (IFN-gamma- and IL-2-producing and CD107a(+)) virus-specific CD8(+) T cells. These polyfunctional T cells are distinguished by the expression of CD127 and Bcl-2 and represent a transitional memory T-cell subset that exhibits the phenotypic and functional signatures of both central and effector memory T cells. In contrast, HCV-specific CD8(+) T cells in acute infections evolving to chronicity expressed low levels of CD127 and Bcl-2, exhibited diminished proliferation and cytokine production, and eventually disappeared from the periphery. Early therapeutic intervention with pegylated IFN-alpha rescued polyfunctional memory T cells expressing high levels of CD127 and Bcl-2. These cells were detectable for up to 1 year following discontinuation of therapy. Our results suggest that the polyfunctionality of HCV-specific T cells can be predictive of the outcome of acute HCV infection and that early therapeutic intervention can reconstitute the pool of long-lived polyfunctional memory T cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18667516      PMCID: PMC2566289          DOI: 10.1128/JVI.01083-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  63 in total

1.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions.

Authors:  F Sallusto; D Lenig; R Förster; M Lipp; A Lanzavecchia
Journal:  Nature       Date:  1999-10-14       Impact factor: 49.962

2.  Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus.

Authors:  N H Gruener; F Lechner; M C Jung; H Diepolder; T Gerlach; G Lauer; B Walker; J Sullivan; R Phillips; G R Pape; P Klenerman
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

3.  Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C.

Authors:  A Takaki; M Wiese; G Maertens; E Depla; U Seifert; A Liebetrau; J L Miller; M P Manns; B Rehermann
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

4.  Protection against persistence of hepatitis C.

Authors:  Shruti H Mehta; Andrea Cox; Donald R Hoover; Xiao-Hong Wang; Qing Mao; Stuart Ray; Steffanie A Strathdee; David Vlahov; David L Thomas
Journal:  Lancet       Date:  2002-04-27       Impact factor: 79.321

5.  Direct ex vivo comparison of the breadth and specificity of the T cells in the liver and peripheral blood of patients with chronic HCV infection.

Authors:  A M Grabowska; F Lechner; P Klenerman; P J Tighe; S Ryder; J K Ball; B J Thomson; W L Irving; R A Robins
Journal:  Eur J Immunol       Date:  2001-08       Impact factor: 5.532

6.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

7.  Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics.

Authors:  Sanaa M Kamal; Alaa Ismail; Camilla S Graham; Qi He; Jens W Rasenack; Thomas Peters; Ahmed A Tawil; Jutta J Fehr; Khalifa El Sayed Khalifa; Mahmoud M Madwar; Margaret James Koziel
Journal:  Hepatology       Date:  2004-06       Impact factor: 17.425

8.  Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C.

Authors:  Sanaa M Kamal; Jutta Fehr; Bernd Roesler; Thomas Peters; Jens W Rasenack
Journal:  Gastroenterology       Date:  2002-10       Impact factor: 22.682

9.  Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection.

Authors:  Heiner Wedemeyer; Xiao-Song He; Michelina Nascimbeni; Anthony R Davis; Harry B Greenberg; Jay H Hoofnagle; T Jake Liang; Harvey Alter; Barbara Rehermann
Journal:  J Immunol       Date:  2002-09-15       Impact factor: 5.422

10.  Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections.

Authors:  Victor Appay; P Rod Dunbar; Margaret Callan; Paul Klenerman; Geraldine M A Gillespie; Laura Papagno; Graham S Ogg; Abigail King; Franziska Lechner; Celsa A Spina; Susan Little; Diane V Havlir; Douglas D Richman; Norbert Gruener; Gerd Pape; Anele Waters; Philippa Easterbrook; Mariolina Salio; Vincenzo Cerundolo; Andrew J McMichael; Sarah L Rowland-Jones
Journal:  Nat Med       Date:  2002-04       Impact factor: 53.440

View more
  75 in total

1.  The analysis of CD45 isoforms expression on HBV-specific T cells after liver transplantation.

Authors:  Lelin Pan; Wenjin Zhang; Jian Zhang; Lin Zhou; Lanjuan Li; Shusen Zheng
Journal:  Med Oncol       Date:  2011-01-30       Impact factor: 3.064

2.  Plasmacytoid dendritic cells control T-cell response to chronic viral infection.

Authors:  Luisa Cervantes-Barragan; Kanako L Lewis; Sonja Firner; Volker Thiel; Stephanie Hugues; Walter Reith; Burkhard Ludewig; Boris Reizis
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-06       Impact factor: 11.205

3.  Hepatitis C virus NS3/NS4A DNA vaccine induces multiepitope T cell responses in rhesus macaques mimicking human immune responses [corrected].

Authors:  Krystle A Lang Kuhs; Arielle A Ginsberg; Jian Yan; Roger W Wiseman; Amir S Khan; Niranjan Y Sardesai; David H O'Connor; David B Weiner
Journal:  Mol Ther       Date:  2011-09-27       Impact factor: 11.454

Review 4.  Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control.

Authors:  Juan-Ramón Larrubia; Elia Moreno-Cubero; Joaquín Miquel; Eduardo Sanz-de-Villalobos
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

5.  Impact of host responses on control of hepatitis C virus infection in Chinese blood donors.

Authors:  Tingting Li; Zixuan Chen; Jinfeng Zeng; Jingang Zhang; Wenjing Wang; Ling Zhang; Xin Zheng; Lifang Shuai; Paul Klenerman; Jean-Pierre Allain; Chengyao Li
Journal:  Biochem Biophys Res Commun       Date:  2011-10-29       Impact factor: 3.575

6.  Acquisition of polyfunctionality by Epstein-Barr virus-specific CD8+ T cells correlates with increased resistance to galectin-1-mediated suppression.

Authors:  Corey Smith; Leone Beagley; Rajiv Khanna
Journal:  J Virol       Date:  2009-04-08       Impact factor: 5.103

7.  The frequency of CD127(+) hepatitis C virus (HCV)-specific T cells but not the expression of exhaustion markers predicts the outcome of acute HCV infection.

Authors:  Eui-Cheol Shin; Su-Hyung Park; Michelina Nascimbeni; Marian Major; Laura Caggiari; Valli de Re; Stephen M Feinstone; Charles M Rice; Barbara Rehermann
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

8.  Interleukin-10 Directly Inhibits CD8+ T Cell Function by Enhancing N-Glycan Branching to Decrease Antigen Sensitivity.

Authors:  Logan K Smith; Giselle M Boukhaled; Stephanie A Condotta; Sabrina Mazouz; Jenna J Guthmiller; Rahul Vijay; Noah S Butler; Julie Bruneau; Naglaa H Shoukry; Connie M Krawczyk; Martin J Richer
Journal:  Immunity       Date:  2018-01-23       Impact factor: 31.745

9.  Human AdV-specific T cells: persisting in vitro functionality despite lethal irradiation.

Authors:  R Geyeregger; C Freimüller; J Stemberger; G Fischer; V Witt; G Fritsch
Journal:  Bone Marrow Transplant       Date:  2014-04-28       Impact factor: 5.483

10.  IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection.

Authors:  David G Brooks; Sang-Jun Ha; Heidi Elsaesser; Arlene H Sharpe; Gordon J Freeman; Michael B A Oldstone
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.